Corporate Finance & Consulting  
 
 
Home Page > Replicon Group
 



Replicon Group becomes Certified Adviser in OMX First North
29-11-2007, ph

Press release, 29-11-2007

Replicon Corporate Finance Ltd gains Certified Adviser (CA) status in OMX First North Helsinki and Stockholm stock exchanges. The ability to assist growth companies in IPOs is an important part of Replicon’s strategy of becoming a major service provider in its chosen market segments in Nordic Countries. Senior Adviser nomination of experienced Matti Copeland, the CEO of A&B, supports the same strategic goal.

First North is an alternative marketplace for small growth companies, providing a world of opportunities on the Nordic and global financial markets. It gives companies greater visibility and ease of access to Northern Europe's largest pool of capital, combining the benefits of being on-market with simplicity. More information: First North

”We are exited on First North as an alternative for raising financing for promising growth companies”, says Petteri Hirvonen CEO of Replicon Group. ”The environment of publicly listed companies is very familiar to me and many of our team from the past. The combination of huge opportunities and challenges of growth companies and the requirements of successful listing could not be more interesting”, Petteri Hirvonen, former Chief Economist and Investment Strategist of Mandatum Bank, adds.

Simultaneously with the CA status, Matti Copeland, CEO of A&B, joins Replicon team as a Senior Adviser. Matti Copeland is a very experienced M&A and corporate finance professional. Further information on Matti Copeland see Link to Matti Copeland

Replicon services, please contact:
+358-(0)9-677 464

Petteri Hirvonen,
CEO, Replicon Group +358-(0)50-552 96 33 (direct)

petteri.hirvonen@replicon.fi About Replicon

Replicon Group is an independent corporate finance, consulting and asset management advisory house for growth companies and growth investors. Replicon provides strategic and financial solutions that facilitate business activities, efficiency, and increase profitability of corporations and other organizations. Our core competence is in the corporate solutions that facilitate and govern growth of businesses based on innovation. An important part of our activities is continuous learning. We want to find and develop most suitable solutions to our customer needs. Replicon Group’s special focus areas are Life-Science and ICT/Mobile sectors. In these sectors Replicon provides also asset management advisory. The main shareholders in Replicon Group are its key management, holding majority of the company’s shares. Replicon’s homepage is www.replicon.fi.

Important Notice: First North is an alternative market, operated by the different exchanges within OMX. It does not have the legal status as an EU-regulated market. Companies at First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.


Recent articles:

> 19-08-2010 - Valuation Services and Total Life Cycle Cost Analyses

> 04-05-2010 - Oversol Oy / Lumi Group Oy Raises First Part of 2-4 M€ Financing

> 22-03-2010 - Replicon Continues as Certified Adviser in NASDAQ OMX First North

> 22-03-2010 - Replicon Group jatkaa NASDAQ OMX:ssä neuvonantajana

> 22-01-2010 - Replicon Initiates Multimillion Financing Project for Promising LED Application

> 06-10-2009 - Replicon Newsletter Q3/2009

> 09-09-2009 - New Certification for Replicon Group

> 24-08-2009 - Replicon toimittaa asiantuntija-palvelupaketin Qentinel Oy:lle

> 17-08-2009 - ASIAVIIHDE: videoidut talouskirja-arvostelut

> 16-06-2009 - Replicon Group Company Awarded 2 Year R&D Project

> 21-05-2009 - Replicon Newsletter Q2/2009

> 21-05-2009 - Repliconin Uutiskirje Q2/2009

> 03-02-2009 - Replicon Newsletter Q1/2009

> 19-01-2009 - Jouko Ahvenainen Presenting in Mobile World Congress in Barcelona

> 19-12-2008 - Replicon Creates an Option Arrangement for Its Client

> 29-10-2008 - Results from Client Survey

> 18-09-2008 - Tuottavuus ja rahoitus 2008 -seminaari

> 17-06-2008 - Ani Biotech buys the Business Operations of Orgenium Laboratories

> 20-05-2008 - Tietoisku FIRST NORTH -markkinapaikasta

> 31-03-2008 - Replicon Collaboration Partner Forms Global Multi-Centre Network

> 30-01-2008 - Replicon helps EVE to Receive Private Equity Financing

> 29-01-2008 - Replicon Pharma Portfolio Outperforms Benchmark Index Fifth Year in a Row

> 29-11-2007 - Replicon Group OMX First Northin Certified Adviseriksi

> 29-11-2007 - Replicon Group becomes Certified Adviser in OMX First North

> 28-11-2007 - Matti Copeland Repliconin neuvonantajaksi

> 15-10-2007 - Replicon Private Equity -tapahtuma

> 24-09-2007 - Talentor Receives Private Equity Financing Package in Record Time

> 07-08-2007 - Meet Replicon in Autumn 2007

> 11-05-2007 - Replicon and Imanext Form Strategic Collaboration

> 17-04-2007 - Pääjohtaja Liikanen puhumassa Repliconin Tuottavuus -seminaarissa

> 17-04-2007 - BoF Governor Speaking at Replicon Productivity Seminar

> 09-03-2007 - Top Seminar: ICT Companies as Productivity Boosters

> 08-03-2007 - Xtract raises € 2 million in venture capital funding from Eqvitec

> 21-02-2007 - ICT-yritykset tuottavuuden nostajina - Repliconin Tuottavuus ja rahoitus -seminaari 17.4.2007

> 29-01-2007 - Replicon MDF Portfolio Outperforms Benchmark Index Fourth Year in a Row

> 29-01-2007 - Repliconin Pharma portfolio (MDF) ylittänyt jälleen vertailuindeksin tuoton

> 08-01-2007 - Replicon toimittaa asiantuntijapalvelupaketin Qentinel Oy:lle

> 15-12-2006 - Replicon Provides Expert Services for Xtract, Ltd.

> 01-11-2006 - Replicon Provides Compensation Arrangement Planning for Growth Companies

> 01-11-2006 - Replicon toteuttaa osakesidonnaisia kannustinjärjestelmiä kasvuyrityksille

> 26-10-2006 - Petteri Hirvonen Presenting in Global UMTS TDD Alliance Summit in London

> 28-09-2006 - Jouko Ahvenainen Presenting in Mobile Marketing Service Summit in Lisbon

> 29-05-2006 - First Half Management Consulting Projects of Replicon

> 01-04-2006 - Replicon Launches Investigational Asset Management Portfolio in ICT sector

> 02-03-2006 - Enfucell Receives First VC Round of Financing

> 20-02-2006 - Replicon Helps Arranging Significant Financing Package for a Client

> 29-01-2006 - Replicon Portfolio Outperforms Benchmark Third Year in a Row

> 02-01-2006 - Replicon Hires Satu Vapaakallio as Analyst

> 24-11-2005 - Replicon Initiate 7.5Meur Private Placement Process for SkyWeb Oy

> 14-10-2005 - CTT Cancer Targeting Technologies Ltd enters into R&D agreement with GE Healthcare

> 05-09-2005 - Orgenium receives financing from Abroad and Expands Production to Low Cost Production Site in Ankara, Turkey

> 20-07-2005 - Replicon helps arranging financing for #CMAX.gg

> 31-03-2005 - Replicon in BioFinland 05 Investor Forum

> 29-01-2005 - Replicon Biotech Value Portfolio Outperforms NASDAQ Biotech Index Second Year in a Row

> 26-01-2005 - Replicon Extends Its Life Science Expert Team

> 18-01-2005 - All Replicon Senior Partners Gain Accreditation by the Ministry of Trade and Industry

> 10-01-2005 - Jouko Ahvenainen (MBA, M.Sc.) joins Replicon as a Senior Partner

> 17-12-2004 - Replicon to Develop a Model for Enhancing Commercialization of Bone Research in Finland

> 29-10-2004 - Replicon moves to WTC Helsinki

> 15-10-2004 - MBA Petri Laulajainen joins Replicon as a Senior Partner

> 02-07-2004 - Orgenium closes financing round with private investors and Finnish Industry Investment Ltd.

> 27-05-2004 - Replicon's new strategic partners announced

> 07-04-2004 - Viope closes financing round for expansion

> 29-01-2004 - Replicon Biotech Model Portfolio Annual Return 78 per cent

> 15-12-2003 - Replicon enters into a two-year business development partnership

> 19-08-2003 - Dr. Hannu Silvennoinen joins as a Senior Partner

> 09-04-2003 - Replicon forms corporate finance unit

> 28-01-2003 - Replicon Launches Model Portfolio in Biotech

 
© 2003, Replicon